matrix metalloproteinase13 mmp13 member collagenase family enzymes implicated play key role pathology osteoarthritis recently reported discovery series quinazoline2carboxamide based nonzincbinding mmp13 selective inhibitors exemplified compound continued research novel class zincbinding inhibitors obtain followup compounds different physicochemical pharmacokinetic biological activity profiles order design selective mmp13 inhibitors adopted strategy connecting zincbinding group quinazoline2carboxamide system unique binder appropriate linker among synthesized compounds triazolone inhibitor exhibited excellent potency icsub50sub0071nm selectivity greater 170fold mmps mmp1 tumor necrosis factor converting enzyme tace article design synthesis biological activity novel zincbinding mmp13 inhibitors described osteoarthritis agerelated degenerative disease characterized chronic joint pain inflammation damage joint cartilage present steroidal drugs nonsteroidal antiinflammatory drugs nsaids selective cyclooxygenase2 cox2 inhibitors firstline drugs treatment however drugs could lead cardiovascular side effects therefore urgent develop novel agents treatment matrix metalloproteinase13 mmp13 important member matrix metalloproteinases mmps family plays vital role degrading type collagen articular cartilage bone noted mmp13 specially expressed patients normal adults addition broadspectrum mmp inhibitors could result painful jointstiffening side effects called musculoskeletal syndrome mss clinical trials thus developing selective mmp13 inhibitors potential strategy therapy review summarize recent progress selective mmp13 inhibitors including two subfamilies namely zincbinding nonzincbinding selective mmp13 inhibitors osteoarthritis common form arthritis available diseasemodifying treatments major cause disability matrix metalloproteinase mmp13 vital progression thus inhibition mmp13 effective strategy treat since past decades drug repurposing gained substantial popularity worldwide time costeffective approach find new indications existing drugs therefore xray cocrystal structures human mmp13 bound inhibitors investigated gain structural insights conserved direct interactions binding site residues namely ala238 thr245 thr247 afterwards enrichment study using active decoy set ligands revealed three mmp13 structures pdbids 1xuc 3wv1 5bpa optimal enrichment performance dockingbased screening existing drugs three crystal structures followed binding freeenergy calculation suggested drugs namely eltrombopag cilostazol domperidone potential mmp13 inhibitors need experimental validation insights may serve potential starting point experimental validation structurebased drug designrepurposing mmp13 inhibitors treatment abbreviations twodimensional threedimensional fda food drug administration mmgbsa molecular mechanics generalized born surface area mmps matrix metalloproteinases mmp13 matrix metalloproteinase nmr nuclear magnetic resonance osteoarthritis pdb protein data bank pdbid protein data bank plip proteinligand interaction profiler roc receiver operating characteristic rmsd root mean square deviation communicated ramaswamy sarma mmp13 belongs large family proteases called matrix metalloproteinases mmps degrades type collagen main structural protein articular cartilage main pathologic role mmp13 expression contribute development osteoarthritis find new inhibitors possible selectivity mmp13 structure based virtual screening employed inhibitory activities inhibitors among purchased compounds approved enzyme inhibition assay results demonstrated cadd computer aided drug design could successfully applied find new mmp13 inhibitors using receptor structure pdb code 3o2x demonstrated good performance crossdocking study discovered inhibitors new scaffolds inhibition mmp13 selectivity features proper occupancy interactions pocket could subjected future lead optimization study matrix metalloproteinase13 mmp13 attractive drug target treatment osteoarthritis study series quinazolinone derivatives mmp13 inhibitors firstly systematically studied using qsar molecular docking molecular dynamics simulation reliable comfa iqisup2sup 0646 irisup2sup 0992 irisubpredsubsup2sup 0829 comsia iqisup2sup 0704 irisup2sup 0992 irisubpredsubsup2sup 0839 models constructed verified topomer comfa model results contour maps indicated electrostatic hydrophobic hbond acceptor fields primarily influenced activity mmp13 inhibitors models several key residues ala238 thr245 thr247 met253 asn215 lys140 identified important factors improve activity stability inhibitor hydrogen bonding electrostatic interaction based results eight novel quinazolinones bd1d8b designed additionally designed compounds showed good pharmacokinetic properties admet predictions compounds bd3b bd8b exhibited excellent predictive activity simulations analysis revealed hydrogen bonding interaction residues ser250 gly248 enhanced small group ushaped conformation pivotal importance results provided strong guidance discovery design novel potential mmp13 inhibitors osteoarthritis degenerative joint disease affecting large population people although elevated expression pkr double stranded rnadependent protein kinase mmp13 collagenase3 indicated play pivotal roles pathogenesis exact mechanism underlying regulation mmp13 pkr following inflammatory stimulation relatively unknown purpose study determine signaling pathway involved pkrmediated induction mmp13 tnfstimulation study cartilages knee joint obtained subjects underwent arthroplastic knee surgery cartilages used tissue analysis chondrocytes isolation results upregulated expression pkr observed damaged cartilages well tnfstimulated chondrocytes phosphorylation pkc protein kinase found tnf administration pkr activation using polyic indicating pkc regulated pkr subsequent increased activity nadph oxidase led oxidative stress accumulation antioxidant capacity downregulation followed exaggerated inflammatory response elevated levels cox2 il8 via erknfb pathway activated erk pathway also impeded inhibition mmp13 ppar findings demonstrated tnfinduced pkr activation triggered oxidative stressmediated inflammation mmp13 human chondrocytes unraveling deregulated signaling cascades deepen knowledge pathophysiology provide aid development novel therapies considering pathological significance mmp13 breast colon cancers exositebased inhibition cterminal hemopexin hpx domain could serve alternative strategy develop selective inhibitors mmp13two six lead compounds compound 23dihydro14benzodioxine5carboxylic acid compound 1acetyl4hydroxypyrrolidine2carboxylic acid exhibited considerable inhibitory activity mmp13 complementing study also shown gene expression levels mmp13 within subtypes colon breast cancers classified patients tissue samples provide better understanding subtype breast cancer patients would get benefited mmp13 inhibitorsour current results show compounds could effectively inhibit mmp13 provide specific therapeutic possibilities treatment inflammatory disorders cancers characterization lead compounds would provide better mechanistic understanding exositebased inhibition mmp13 could overcome challenges identification mmp catalytic domainspecific inhibitors aging one major pathologic factors associated osteoarthritis recently numerous reports demonstrated impact sirtuin1 sirt1 naddependent deacetylase human aging demonstrated sirt1 induces osteogenic chondrogenic differentiation mesenchymal stem cells however role sirt1 chondrocytes still remains unknown postulated sirt1 regulates hypertrophic chondrocyte lineage degeneration articular cartilage activation osteogenic transcriptional activator runx2 matrix metalloproteinase mmp13 chondrocytes verify whether sirtuin1 sirt1 regulates chondrocyte activity studied expressions sirt1 runx2 production mmp13 associations human chondrocytes expression sirt1 ubiquitously observed osteoarthritic chondrocytes contrast runx2 expressed osteophyte region patients model mice relating catabolic factor il1increased expression runx2 chondrocytes chondrocytes pretreated sirt1 inhibitor inhibited il1induced expression runx2 compared control since runx2 promotor mmp13 expression sirt1 inactivation may inhibit runx2 expression resultant downregulation mmp13 production chondrocytes findings suggest thatsirt1 may regulate expression runx2 osteogenic transcription factor production mmp13 chondrocytes since sirt1 activity known affected several stresses including inflammation oxidative stress well aging sirt may involved development matrix metalloproteinases mmps zinc enzymes responsible degradation extracellular matrix function mmps involved many physiological processes also many pathological states mmp13 implicated degradation type collagen main structural protein articular cartilage contributing development osteoarthritis inflammatory diseases last years new generation potent selective mmp inhibitors mmpis identified classified nonzincbinding inhibitors nzbis several mmp13 nzbis developed crystallographically determined complex enzyme provide detailed review current knowledge class mmp13 inhibitors using computational procedures highlight molecular determinants needed binding process particular flap program based grid molecular interaction fields used analyze ligandprotein interactions molecular shape hydrogen bond acceptor groups strongly influence binding according ligandbased modeling aromatic interactions better identified structurebased study complementary results combined high performance model showing effectiveness molecular interaction field based approaches search novel mmp13 nzbis krppellike factor klf2 plays essential role inhibition endothelial cell macrophage activation inflammatory process however roles klf2 chondrocytes pathological progression osteoarthritis remain unknown aim study investigate function klf2 inhibition cartilage matrix destruction chondrocytes rtpcr western blot analysis used determine expression klf2 human chondrocytes luciferase assay elisa assay mmp13 enzymatic activity assays used investigate effects klf2 regulating mmp13 expression western blot analysis used examine effects klf2 suppressing degradation type collagen klf2 expressed primary chondrocytes downregulated chondrocytes expression klf2 primary chondrocytes reduced response il1 overexpression klf2 robustly inhibited il1induced mmp13 expression conversely knockdown klf2 markedly exacerbated mmp13 expression mechanistically klf2 could suppress activation mmp13 promoter however knockdown klf2 could promote activation mmp13 promoter importantly overexpression klf2 ameliorated degradation type collagen silencing klf2 exacerbated degradation type collagen induced il1 klf2 may potential therapeutic target treatment 
matrix metalloproteinase13 mmp13 member collagenas famili enzym implic play key role patholog osteoarthr recent report discoveri seri quinazoline2carboxamid base nonzincbind mmp13 select inhibitor exemplifi compound continu research novel class zincbind inhibitor obtain followup compound differ physicochem pharmacokinet biolog activ profil order design select mmp13 inhibitor adopt strategi connect zincbind group quinazoline2carboxamid system uniqu binder appropri linker among synthes compound triazolon inhibitor exhibit excel potenc icsub50sub0071nm select greater 170fold mmp mmp1 tumor necrosi factor convert enzym tace thi articl design synthesi biolog activ novel zincbind mmp13 inhibitor describ osteoarthr agerel degen diseas character chronic joint pain inflamm damag joint cartilag present steroid drug nonsteroid antiinflammatori drug nsaid select cyclooxygenase2 cox2 inhibitor firstlin drug treatment howev drug could lead cardiovascular side effect therefor urgent develop novel agent treatment matrix metalloproteinase13 mmp13 import member matrix metalloproteinas mmp famili play vital role degrad type collagen articular cartilag bone note mmp13 special express patient normal adult addit broadspectrum mmp inhibitor could result pain jointstiffen side effect call musculoskelet syndrom mss clinic trial thu develop select mmp13 inhibitor potenti strategi therapi thi review summar recent progress select mmp13 inhibitor includ two subfamili name zincbind nonzincbind select mmp13 inhibitor osteoarthr common form arthriti avail diseasemodifi treatment major caus disabl matrix metalloproteinas mmp13 vital progress thu inhibit mmp13 effect strategi treat sinc past decad drug repurpos gain substanti popular worldwid time costeffect approach find new indic exist drug therefor xray cocryst structur human mmp13 bound inhibitor investig gain structur insight conserv direct interact bind site residu name ala238 thr245 thr247 afterward enrich studi use activ decoy set ligand reveal three mmp13 structur pdbid 1xuc 3wv1 5bpa optim enrich perform dockingbas screen exist drug three crystal structur follow bind freeenergi calcul suggest drug name eltrombopag cilostazol domperidon potenti mmp13 inhibitor need experiment valid insight may serv potenti start point experiment valid structurebas drug designrepurpos mmp13 inhibitor treatment abbrevi twodimension threedimension fda food drug administr mmgbsa molecular mechan gener born surfac area mmp matrix metalloproteinas mmp13 matrix metalloproteinas nmr nuclear magnet reson osteoarthr pdb protein data bank pdbid protein data bank plip proteinligand interact profil roc receiv oper characterist rmsd root mean squar deviat commun ramaswami sarma mmp13 belong larg famili proteas call matrix metalloproteinas mmp degrad type collagen main structur protein articular cartilag main patholog role mmp13 express contribut develop osteoarthr find new inhibitor possibl select mmp13 structur base virtual screen employ inhibitori activ inhibitor among purchas compound approv enzym inhibit assay result demonstr cadd comput aid drug design could success appli find new mmp13 inhibitor use receptor structur pdb code 3o2x demonstr good perform crossdock studi discov inhibitor new scaffold inhibit mmp13 select featur proper occup interact pocket could subject futur lead optim studi matrix metalloproteinase13 mmp13 attract drug target treatment osteoarthr thi studi seri quinazolinon deriv mmp13 inhibitor firstli systemat studi use qsar molecular dock molecular dynam simul reliabl comfa iqisup2sup 0646 irisup2sup 0992 irisubpredsubsup2sup 0829 comsia iqisup2sup 0704 irisup2sup 0992 irisubpredsubsup2sup 0839 model construct verifi topom comfa model result contour map indic electrostat hydrophob hbond acceptor field primarili influenc activ mmp13 inhibitor model sever key residu ala238 thr245 thr247 met253 asn215 lys140 identifi import factor improv activ stabil inhibitor hydrogen bond electrostat interact base result eight novel quinazolinon bd1d8b design addit design compound show good pharmacokinet properti admet predict compound bd3b bd8b exhibit excel predict activ simul analysi reveal hydrogen bond interact residu ser250 gly248 enhanc small group ushap conform pivot import result provid strong guidanc discoveri design novel potenti mmp13 inhibitor osteoarthr degen joint diseas affect larg popul peopl although elev express pkr doubl strand rnadepend protein kinas mmp13 collagenase3 indic play pivot role pathogenesi exact mechan underli regul mmp13 pkr follow inflammatori stimul rel unknown purpos thi studi determin signal pathway involv pkrmediat induct mmp13 tnfstimul thi studi cartilag knee joint obtain subject underw arthroplast knee surgeri cartilag use tissu analysi chondrocyt isol result upregul express pkr observ damag cartilag well tnfstimul chondrocyt phosphoryl pkc protein kinas found tnf administr pkr activ use polyic indic pkc regul pkr subsequ increas activ nadph oxidas led oxid stress accumul antioxid capac downregul follow exagger inflammatori respons elev level cox2 il8 via erknfb pathway activ erk pathway also imped inhibit mmp13 ppar find demonstr tnfinduc pkr activ trigger oxid stressmedi inflamm mmp13 human chondrocyt unravel deregul signal cascad deepen knowledg pathophysiolog provid aid develop novel therapi consid patholog signific mmp13 breast colon cancer exositebas inhibit ctermin hemopexin hpx domain could serv altern strategi develop select inhibitor mmp13two six lead compound compound 23dihydro14benzodioxine5carboxyl acid compound 1acetyl4hydroxypyrrolidine2carboxyl acid exhibit consider inhibitori activ mmp13 complement thi studi also shown gene express level mmp13 within subtyp colon breast cancer classifi patient tissu sampl provid better understand subtyp breast cancer patient would get benefit mmp13 inhibitorsour current result show compound could effect inhibit mmp13 provid specif therapeut possibl treatment inflammatori disord cancer character lead compound would provid better mechanist understand exositebas inhibit mmp13 could overcom challeng identif mmp catalyt domainspecif inhibitor age one major patholog factor associ osteoarthr recent numer report demonstr impact sirtuin1 sirt1 naddepend deacetylas human age demonstr sirt1 induc osteogen chondrogen differenti mesenchym stem cell howev role sirt1 chondrocyt still remain unknown postul sirt1 regul hypertroph chondrocyt lineag degener articular cartilag activ osteogen transcript activ runx2 matrix metalloproteinas mmp13 chondrocyt verifi whether sirtuin1 sirt1 regul chondrocyt activ studi express sirt1 runx2 product mmp13 associ human chondrocyt express sirt1 ubiquit observ osteoarthrit chondrocyt contrast runx2 express osteophyt region patient model mice relat catabol factor il1increas express runx2 chondrocyt chondrocyt pretreat sirt1 inhibitor inhibit il1induc express runx2 compar control sinc runx2 promotor mmp13 express sirt1 inactiv may inhibit runx2 express result downregul mmp13 product chondrocyt find suggest thatsirt1 may regul express runx2 osteogen transcript factor product mmp13 chondrocyt sinc sirt1 activ known affect sever stress includ inflamm oxid stress well age sirt may involv develop matrix metalloproteinas mmp zinc enzym respons degrad extracellular matrix thi function mmp involv mani physiolog process also mani patholog state mmp13 implic degrad type collagen main structur protein articular cartilag contribut develop osteoarthr inflammatori diseas last year new gener potent select mmp inhibitor mmpi identifi classifi nonzincbind inhibitor nzbi sever mmp13 nzbi develop crystallograph determin complex enzym provid detail review current knowledg thi class mmp13 inhibitor use comput procedur highlight molecular determin need bind process particular flap program base grid molecular interact field use analyz ligandprotein interact molecular shape hydrogen bond acceptor group strongli influenc bind accord ligandbas model aromat interact better identifi structurebas studi complementari result combin high perform model show effect molecular interact field base approach search novel mmp13 nzbi krppellik factor klf2 play essenti role inhibit endotheli cell macrophag activ dure inflammatori process howev role klf2 chondrocyt patholog progress osteoarthr remain unknown aim thi studi investig function klf2 inhibit cartilag matrix destruct chondrocyt rtpcr western blot analysi use determin express klf2 human chondrocyt luciferas assay elisa assay mmp13 enzymat activ assay use investig effect klf2 regul mmp13 express western blot analysi use examin effect klf2 suppress degrad type collagen klf2 express primari chondrocyt downregul chondrocyt express klf2 primari chondrocyt reduc respons il1 overexpress klf2 robustli inhibit il1induc mmp13 express convers knockdown klf2 markedli exacerb mmp13 express mechanist klf2 could suppress activ mmp13 promot howev knockdown klf2 could promot activ mmp13 promot importantli overexpress klf2 amelior degrad type collagen silenc klf2 exacerb degrad type collagen induc il1 klf2 may potenti therapeut target treatment 
['cartilag', 'regener', 'requir', 'balanc', 'anabol', 'catabol', 'process', 'examin', 'suscept', 'fibromodulin', 'fmod', 'lumican', 'lum', 'degrad', 'mmp13', 'adamts4', 'adamts5', 'three', 'major', 'degrad', 'proteinas', 'articular', 'cartilag', 'cartilag', 'develop', 'osteoarthr', 'immunoloc', 'fmod', 'lum', 'fetal', 'foot', 'adult', 'knee', 'cartilag', 'use', 'fmod', 'matrix', 'metalloproteas', 'mmp13', 'neoepitop', 'antibodi', 'tsyg11', 'ctermin', 'antifmod', 'pr184', 'antilum', 'pr353', 'antibodi', 'vitro', 'digest', 'knee', 'cartilag', 'mmp13', 'disintegrin', 'metalloproteas', 'thrompospondin', 'motif', 'adamts4', 'adamts5', 'assess', 'whether', 'fmod', 'lum', 'fragment', 'observ', 'western', 'blot', 'total', 'knee', 'replac', 'specimen', 'could', 'gener', 'normal', 'ovin', 'articular', 'cartilag', 'explant', 'cultur', 'interleukin', 'il1', 'oncostatinm', 'osm', 'pge3162689', 'broad', 'spectrum', 'mmp', 'inhibitor', 'assess', 'fmod', 'lum', 'collagen', 'degrad', 'fmod', 'lum', 'immunoloc', 'metatars', 'phalang', 'fetal', 'rudiment', 'cartilag', 'growth', 'plate', 'antibodi', 'tsyg11', 'local', 'mmp13cleav', 'fmod', 'hypertroph', 'chondrocyt', 'metatars', 'growth', 'plate', 'fmod', 'promin', 'local', 'superfici', 'cartilag', 'normal', 'fibril', 'zone', 'cartilag', 'tsyg11posit', 'fmod', 'locat', 'deep', 'cartilag', 'sampl', 'tsyg11', 'identifi', 'fmod', 'fragment', 'western', 'blot', 'normal', 'fibril', 'cartilag', 'extract', 'total', 'knee', 'replac', 'cartilag', 'ctermin', 'antifmod', 'pr184', 'fail', 'identifi', 'fmod', 'fragment', 'due', 'ctermin', 'process', 'ctermin', 'lum', 'pr353', 'identifi', 'three', 'lum', 'fragment', 'cartilag', 'vitro', 'digest', 'human', 'knee', 'cartilag', 'mmp13', 'adamts4', 'adamts5', 'gener', 'fmod', 'fragment', 'kda', 'similar', 'blot', 'cartilag', 'lum', 'less', 'suscept', 'fragment', 'pr353', 'detect', 'ntermin', 'process', 'lum', 'fragment', 'kda', '6580yearold', 'knee', 'replac', 'cartilag', 'fmod', 'lum', 'differenti', 'process', 'mmp13', 'adamts4', 'adamts5', 'digest', 'fmod', 'suscept', 'degrad', 'mmp13', 'adamts4', 'lesser', 'extent', 'adamts5', 'howev', 'lum', 'mmp13cleav', 'fmod', 'metatars', 'phalang', 'fetal', 'rudiment', 'growth', 'plate', 'cartilag', 'suggest', 'role', 'skeletogenesi', 'pathogenesi', 'explant', 'cultur', 'ovin', 'cartilag', 'stimul', 'il1osm', 'pge3162689', 'display', 'gag', 'loss', 'day', 'due', 'adamt', 'activ', 'howev', 'day', 'activ', 'prommp', 'occur', 'well', 'degrad', 'fmod', 'collagen', 'chang', 'inhibit', 'pge3162689', 'partli', 'explain', 'fmod', 'fragment', 'seen', 'potenti', 'therapeut', 'util', 'pge3162689'] ['matrix', 'metalloproteinas', 'mmp', 'class', 'zinc', 'depend', 'endopeptidas', 'play', 'crucial', 'role', 'multitud', 'sever', 'diseas', 'cancer', 'osteoarthr', 'employ', 'mmp13', 'target', 'enzym', 'structurebas', 'design', 'synthesi', 'inhibitor', 'abl', 'recogn', 'catalyt', 'zinc', 'ion', 'addit', 'alloster', 'bind', 'site', 'order', 'increas', 'affin', 'ligand', 'guid', 'molecular', 'model', 'optim', 'initi', 'alloster', 'inhibitor', 'addit', 'linker', 'fragment', 'weak', 'zinc', 'binder', 'recognit', 'catalyt', 'center', 'furthermor', 'improv', 'lipophil', 'ligand', 'effici', 'lle', 'initi', 'inhibitor', 'appropri', 'zinc', 'bind', 'fragment', 'lower', 'clogp', 'valu', 'inhibitor', 'maintain', 'potenc', 'synthes', 'inhibitor', 'show', 'elev', 'affin', 'compar', 'initi', 'hit', 'also', 'novel', 'inhibitor', 'display', 'better', 'lle', 'deriv', 'carboxyl', 'acid', 'zinc', 'bind', 'fragment', 'turn', 'potent', 'inhibitor', 'compound', 'zhawoc5077', 'ic50', '134', 'wherea', 'acyl', 'sulfonamid', 'show', 'best', 'lipophil', 'ligand', 'effici', 'compound', 'zhawoc5135', 'lle', '291'] ['sustain', 'inflamm', 'matrix', 'metalloproteinas', 'mmp', 'activ', 'contribut', 'vascular', 'occlusiveprolif', 'disord', 'interleukin17', 'il17', 'proinflammatori', 'cytokin', 'signal', 'mainli', 'via', 'traf3', 'interact', 'protein', 'traf3ip2', 'upstream', 'regul', 'variou', 'critic', 'transcript', 'factor', 'includ', 'ap1', 'nfb', 'reversionxa0induc', 'cysteinexa0rich', 'protein', 'kazal', 'motif', 'reck', 'membraneanchor', 'mmp', 'inhibitor', 'investig', 'whether', 'il17atraf3ip2', 'signal', 'promot', 'mmp13depend', 'human', 'aortic', 'smooth', 'muscl', 'cell', 'smc', 'prolifer', 'migrat', 'determin', 'whether', 'reck', 'overexpress', 'blunt', 'respons', 'inde', 'il17a', 'treatment', 'induc', 'jnk', 'p38', 'mapk', 'ap1', 'nfb', 'creb', 'activ', 'mir21', 'induct', 'mir27b', 'mir320', 'inhibit', 'mmp13', 'express', 'activ', 'reck', 'suppress', 'smc', 'migrat', 'prolifer', 'traf3ip2depend', 'manner', 'fact', 'gain', 'trag3ip2', 'function', 'induc', 'mmp13', 'express', 'activ', 'reck', 'suppress', 'furthermor', 'treatment', 'recombin', 'mmp13', 'stimul', 'smc', 'migrat', 'part', 'via', 'erk', 'activ', 'importantli', 'reck', 'gainoffunct', 'attenu', 'mmp13', 'activ', 'without', 'affect', 'mrna', 'protein', 'level', 'inhibit', 'il17a', 'mmp13induc', 'smc', 'migrat', 'result', 'indic', 'increas', 'mmp13', 'decreas', 'reck', 'contribut', 'il17ainduc', 'traf3ip2depend', 'smc', 'migrat', 'prolifer', 'suggest', 'traf3ip2', 'inhibitor', 'reck', 'induc', 'potenti', 'block', 'progress', 'neointim', 'thicken', 'hyperplast', 'vascular', 'diseas'] ['complic', 'diabet', 'neuropathi', 'condit', 'sensori', 'axon', 'degener', 'origin', 'epidermi', 'mechan', 'remain', 'unknown', 'reactiv', 'oxygen', 'speci', 'implic', 'thi', 'condit', 'thi', 'studi', 'assess', 'role', 'candid', 'downstream', 'target', 'mmp13', 'glucoseinduc', 'sensori', 'axon', 'degener', 'zebrafish', 'mice', 'effect', 'glucos', 'metabol', 'sensori', 'axon', 'degener', 'assess', 'use', 'qpcr', 'live', 'imag', 'analyz', 'use', 'pentafluorobenzenesulfonyl', 'fluorescein', 'activ', 'nfb', 'stress', 'respons', 'determin', 'use', 'tgnfbgfp', 'zebrafish', 'role', 'mmp13', 'glucosedepend', 'axon', 'degener', 'determin', 'zebrafish', 'follow', 'treatment', 'antioxid', 'nacetylcystein', 'mmp13', 'inhibitor', 'db04760', 'neuropath', 'mice', 'fed', 'highfathighsugar', 'diet', 'treat', 'mmp13', 'inhibitor', 'cl82198', 'assess', 'sensori', 'recoveri', 'glucos', 'treatment', 'zebrafish', 'induc', 'metabol', 'chang', 'resembl', 'diabet', 'sensori', 'axon', 'degener', 'mediat', 'rosinduc', 'mmp13', 'prevent', 'upon', 'antioxid', 'treatment', 'mmp13', 'inhibit', 'mmp13', 'inhibit', 'also', 'revers', 'neuropathi', 'diabet', 'mice', 'demonstr', 'zebrafish', 'suitabl', 'studi', 'glucoseinduc', 'neurotox', 'given', 'effect', 'zebrafish', 'mice', 'mmp13', 'inhibit', 'may', 'benefici', 'treatment', 'human', 'diabet', 'neuropathi'] ['adam8', 'report', 'promot', 'extracellular', 'matrix', 'degrad', 'provid', 'condit', 'tumor', 'metastasi', 'howev', 'underli', 'mechan', 'adam8', 'modul', 'chondrosarcoma', 'metastasi', 'remain', 'unclear', 'use', 'two', 'human', 'cell', 'line', 'sw1353', 'hcs28', 'analyz', 'express', 'profil', 'adam8', 'cell', 'compar', 'normal', 'chondrocyt', 'import', 'proteolyt', 'enzym', 'mmp13', 'detect', 'marker', 'extracellular', 'matrix', 'degrad', 'chondrocyt', 'silenc', 'overexpress', 'adam8', 'effect', 'cell', 'migrat', 'invas', 'sw1353', 'hcs28', 'downstream', 'signal', 'transduct', 'pathway', 'evalu', 'adam8', 'mmp13', 'highli', 'express', 'nfb', 'pathway', 'activ', 'sw1353', 'hcs28', 'cell', 'silenc', 'adam8', 'significantli', 'reduc', 'abil', 'cell', 'migrat', 'invas', 'block', 'nfb', 'signal', 'pathway', 'p65', 'dephosphoryl', 'lead', 'reduc', 'nfb', 'transcript', 'activ', 'decreas', 'mmp13', 'express', 'adam8', 'overexpress', 'promot', 'process', 'howev', 'revers', 'inhibitor', 'bay', '117085', 'data', 'show', 'novel', 'regul', 'mechan', 'adam8', 'promot', 'migrat', 'invas', 'activ', 'nfbmmp13', 'signal', 'axi', 'modul', 'level', 'may', 'serv', 'potenti', 'target', 'treatment', 'even', 'cartilag', 'diseas'] ['patholog', 'progress', 'osteoarthr', 'involv', 'degrad', 'articular', 'cartilag', 'matrix', 'type', 'collagen', 'main', 'compon', 'cartilag', 'matrix', 'degrad', 'proinflammatori', 'cytokin', 'il1', 'mediat', 'mmp13', 'nebivolol', 'licens', 'drug', 'use', 'treatment', 'hypertens', 'clinic', 'display', 'antiinflammatori', 'capac', 'variou', 'condit', 'howev', 'whether', 'nebivolol', 'protect', 'effect', 'cartilag', 'matrix', 'degrad', 'report', 'befor', 'thi', 'studi', 'investig', 'effect', 'nebivolol', 'regul', 'express', 'mmp13', 'degrad', 'type', 'collagen', 'result', 'indic', 'nebivolol', 'allevi', 'increas', 'gene', 'express', 'protein', 'express', 'activ', 'mmp13', 'induc', 'il1', 'importantli', 'il1', 'strikingli', 'reduc', 'level', 'type', 'collagen', 'cell', 'cultur', 'supernat', 'revers', 'treatment', 'nebivolol', 'dosedepend', 'manner', 'mechanist', 'nebivolol', 'found', 'allevi', 'increas', 'level', 'phosphoryl', 'reduc', 'level', 'total', 'induc', 'il1', 'subsequ', 'mitig', 'p65', 'nuclear', 'transloc', 'transcript', 'activ', 'nfb', 'furthermor', 'result', 'indic', 'il1', 'treatment', 'result', 'signific', 'increas', 'express', 'transcript', 'factor', 'interferon', 'regulatori', 'factor1', 'irf1', 'mrna', 'protein', 'level', 'significantli', 'amelior', 'treatment', 'nebivolol', 'combin', 'find', 'suggest', 'nebivolol', 'potenti', 'appli', 'human', 'treatment'] ['matrix', 'metalloproteinas', 'mmp', 'inhibitor', 'play', 'role', 'pathobiolog', 'retin', 'detach', 'prolif', 'vitreoretinopathi', 'pvr', 'prolif', 'vitreoretinopathi', 'facilit', 'chronic', 'retin', 'detach', 'involv', 'excess', 'deposit', 'extracellular', 'matrix', 'ecm', 'protein', 'matrix', 'metalloproteinase2', 'import', 'modul', 'ecm', 'evalu', 'purpos', 'thi', 'studi', 'investig', 'retin', 'express', 'select', 'mmp', 'includ', 'mmp12', 'mmp13', 'associ', 'inhibitor', 'murin', 'model', 'retin', 'detach', 'transient', 'chronic', 'retin', 'detach', 'induc', 'subretin', 'inject', 'either', 'salin', 'hyaluron', 'acid', 'c57bl6', 'mice', 'confirm', 'hard', 'model', 'featur', 'consist', 'pvrlike', 'chang', 'glial', 'activ', 'subretin', 'fibrosi', 'evalu', 'immunofluoresc', 'dilat', 'fundu', 'examin', 'spectraldomain', 'optic', 'coher', 'tomographi', 'sdoct', 'gene', 'express', 'quantifi', 'qrtpcr', 'protein', 'assay', 'immunoblot', 'immunohistochemistri', 'hyaluron', 'acid', 'eye', 'develop', 'gliosi', 'subretin', 'fibrosi', 'dilat', 'exam', 'sdoct', 'immunofluoresc', 'analysi', 'gene', 'express', 'mmp12', 'mmp13', 'timp1', 'strongli', 'upregul', 'time', 'point', 'compar', 'control', 'timp2', 'mmp2', 'mmp9', 'express', 'modest', 'hyaluron', 'acid', 'exhibit', 'mmp', 'timp', 'express', 'sard', 'mmp12', 'timp1', 'protein', 'elev', 'compar', 'control', 'immunohistochemistri', 'reveal', 'moder', 'strong', 'mmp13', 'level', 'subretin', 'space', 'macrophag', 'fibrosi', 'develop', 'hard', 'model', 'upregul', 'select', 'mmp', 'may', 'modul', 'wound', 'heal', 'process', 'follow'] ['matrix', 'metalloproteinase13', 'mmp13', 'attract', 'drug', 'target', 'treatment', 'osteoarthr', 'thi', 'studi', 'seri', 'quinazolinon', 'deriv', 'mmp13', 'inhibitor', 'firstli', 'systemat', 'studi', 'use', 'qsar', 'molecular', 'dock', 'molecular', 'dynam', 'simul', 'reliabl', 'comfa', 'iqisup2sup', '0646', 'irisup2sup', '0992', 'irisubpredsubsup2sup', '0829', 'comsia', 'iqisup2sup', '0704', 'irisup2sup', '0992', 'irisubpredsubsup2sup', '0839', 'model', 'construct', 'verifi', 'topom', 'comfa', 'model', 'result', 'contour', 'map', 'indic', 'electrostat', 'hydrophob', 'hbond', 'acceptor', 'field', 'primarili', 'influenc', 'activ', 'mmp13', 'inhibitor', 'model', 'sever', 'key', 'residu', 'ala238', 'thr245', 'thr247', 'met253', 'asn215', 'lys140', 'identifi', 'import', 'factor', 'improv', 'activ', 'stabil', 'inhibitor', 'hydrogen', 'bond', 'electrostat', 'interact', 'base', 'result', 'eight', 'novel', 'quinazolinon', 'bd1d8b', 'design', 'addit', 'design', 'compound', 'show', 'good', 'pharmacokinet', 'properti', 'admet', 'predict', 'compound', 'bd3b', 'bd8b', 'exhibit', 'excel', 'predict', 'activ', 'simul', 'analysi', 'reveal', 'hydrogen', 'bond', 'interact', 'residu', 'ser250', 'gly248', 'enhanc', 'small', 'group', 'ushap', 'conform', 'pivot', 'import', 'result', 'provid', 'strong', 'guidanc', 'discoveri', 'design', 'novel', 'potenti', 'mmp13', 'inhibitor'] ['matrix', 'metalloproteinas', 'like', 'mmp13', 'cleav', 'remodel', 'extracellular', 'matrix', 'therebi', 'play', 'crucial', 'role', 'tumor', 'progress', 'vivo', 'use', 'highli', 'select', 'inhibitor', 'block', 'mmp13', 'protein', 'activ', 'demonstr', 'strike', 'inhibitori', 'effect', 'invas', 'tumor', 'growth', 'vascular', 'murin', 'skin', 'squamou', 'cell', 'carcinoma', 'scc', 'therapi', 'outcom', 'critic', 'depend', 'anim', 'age', 'c57bl6', 'mice', 'success', 'old', 'femal', 'young', 'femal', 'mice', 'treatment', 'success', 'recov', 'ovariectomi', 'young', 'abolish', '17estradiol', 'supplement', 'old', 'mice', 'suggest', 'hormon', 'depend', 'inhibitor', 'effect', 'respons', 'tumorigen', 'keratinocyt', 'bdvii', 'fibroblast', '17estradiol', 'confirm', 'vitro', 'mmp13', 'inhibitor', 'treatment', 'led', 'reduct', 'cell', 'invas', 'vascular', 'endotheli', 'growth', 'factor', 'vegf', 'releas', 'thi', 'correl', 'well', 'less', 'invas', 'vascular', 'tumor', 'treat', 'mice', 'vivo', '17estradiol', 'supplement', 'also', 'reduc', 'invas', 'vegf', 'releas', 'vitro', 'addit', 'reduct', 'mmp13', 'inhibitor', 'treatment', 'thi', 'suggest', 'low', '17estradiol', 'level', 'old', 'mice', 'vivo', 'lead', 'enhanc', 'mmp13', 'level', 'vegf', 'releas', 'allow', 'effect', 'inhibitor', 'treatment', 'compar', 'young', 'mice', 'studi', 'present', 'strong', 'link', 'lower', 'estrogen', 'level', 'old', 'femal', 'mice', 'elev', 'mmp13', 'level', 'result', 'effect', 'mmp13', 'inhibitor', 'treatment', 'fibroblast', 'scc', 'cell', 'vitro', 'vivo'] ['adipos', 'tissu', 'remodel', 'matrix', 'metalloproteas', 'mmp', 'critic', 'tissu', 'hypertrophi', 'obes', 'mmp13', 'import', 'protein', 'highli', 'express', 'adipos', 'tissu', 'whose', 'potenti', 'role', 'adipos', 'tissu', 'expans', 'poorli', 'character', 'investig', 'effect', 'pharmacolog', 'inhibit', 'mmp13', 'select', 'inhibitor', 'cp544439', 'adipos', 'tissu', 'mass', 'mice', 'high', 'fat', 'diet', 'determin', 'effect', 'inhibitor', 'dure', 'vitro', 'adipocyt', 'differenti', '3t3l1', 'cell', 'cp544439', 'administ', 'week', 'mice', 'high', 'fat', 'diet', 'bodi', 'adipos', 'glucos', 'toler', 'determin', 'differenti', '3t3l1', 'adipocyt', 'also', 'treat', 'inhibitor', 'maximum', 'day', 'adipogenesi', 'assess', 'treatment', 'mice', 'inhibitor', 'result', 'reduct', 'bodi', 'adipos', 'improv', 'glucos', 'clearanc', 'histolog', 'examin', 'epididym', 'adipos', 'show', 'reduc', 'adipocyt', 'hypertrophi', 'accompani', 'increas', 'stain', 'collagen', 'inhibitor', 'treat', 'mice', 'treatment', 'differenti', '3t3l1', 'cell', 'inhibitor', 'result', 'reduc', 'adipocyt', 'differenti', 'knockdown', 'mmp13', 'use', 'small', 'interf', 'rna', 'differenti', '3t3l1', 'cell', 'reduc', 'adipocyt', 'differenti', 'indic', 'reduc', 'express', 'ppar', 'result', 'suggest', 'mmp13', 'may', 'play', 'major', 'role', 'adipos', 'develop', 'inhibit', 'could', 'potenti', 'strategi', 'prevent', 'obes'] 
